IU Health Bloomington understands that clinical research is an important contributor to patient satisfaction and improved clinical outcomes. The hospital is committed to aggressively developing a robust research environment in order to better serve the surrounding community and improve access to care throughout the IU Health System.
Our commitment to developing and maintaining a collaborative research environment allows our physicians to explore a variety of treatment options and allows them to provide cutting-edge therapies to their patients. Below is a list of the clinical trials available for participation at IU Health Bloomington. Please contact the IU Health Bloomington research office 812.353.2831 or BLM-ClinicalResearch@IUHealth.org for more information.
The Indiana Biobank
A collection of a blood sample and personal health information for use in future research studies
Head and Neck Cancer
RTOG 0920 PI-Fred Wu, MD
RTOG 0920 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer.
ECOG E1A11 PI-Jeff Allerton, MD
E1A11 Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Myelodysplastic Syndromes and Acute Myeloid Leukemia
CONNECT PI – Jeffrey Allerton, MD
The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
NSABP B-55 Olympia
Jeffrey Allerton, MD and Karuna Koneru, MD
A Randomised, Double-Blind, Parallel Group< Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA ½ Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
SWOG 1216 PI-Jeffrey Allerton, MD
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
TR(ACE)® Assay Clinical Specimen Study
Jeffrey Allerton, MD Danielle Doyle, MD and Karuna Koneru, MD
Evaluation of the TR(ACE)® Assay for the Ability to Aid in Monitoring Disease Progress, Response to Therapy or for the Recurrent or Residual Disease for Patients with Previously Diagnosed Cancers (Stage III or IV Lung and Stage IV Breast)
The Breast cancer WEight Loss (BWEL) Study
Dr. David Lee
Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (Alliance 011401)